Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 8577 - 8584 of 12038 results
Lost Profit Damages: Key Massachusetts Appellate Cases
February 11, 2016| News
Negative Assurance Letters in EB-5 Offerings
February 11, 2016| News
Costs and Practicalities of Utilizing Alternative Sources of Capital for New Acquisitions, Refinancings & Development
February 11, 2016| Blog| Viewpoint
Solar Installation Boom Expected to Continue in 2016
February 10, 2016| Blog| Viewpoint
Deciphering the Final AMP Rule – Key Provisions Impacting Pharmacies, PBMs, and Manufacturers
February 10, 2016| Advisory| Viewpoint
First Monoclonal Antibody Biosimilar in U.S. Gets One Step Closer to FDA Approval
February 10, 2016| Blog| Viewpoint
CMS Takes Action Against Network Transparency While New Jersey Legislation Hits a Snag
February 10, 2016| Blog| Viewpoint
Positive FDA Advisory Committee Vote for First Monoclonal Antibody Biosimilar - But Will Patent Dispute Delay Launch?
February 10, 2016| Blog| Viewpoint
News & Press Releases
San Francisco Business Times featured Mintz’s new office lease in San Francisco at 525 Market St. The firm will be increasing its footprint in downtown by 50% to 29,000 square feet on a whole single floor with the new space.
Mintz advised the underwriters in connection with a $230 million public offering by Cogent Biosciences, Inc. of 25,555,556 shares of common stock, which includes 3,333,333 shares issued pursuant to the exercise in full by the underwriters of their option to purchase additional shares of common stock, offered at a public offering price of $9.00 per share. The aggregate gross proceeds to Cogent from this offering were approximately $230 million, including proceeds from the exercise in full by the underwriters of the option to purchase additional shares, before deducting underwriting discounts and commissions and other offering expenses.
Mintz advised the underwriters in connection with a $200 million public offering by Soleno Therapeutics, Inc. of 2,352,941 shares of its common stock at a price to the public of $85.00 per share. The gross proceeds to Soleno from the offering were approximately $200 million before deducting underwriting discounts and commissions and other offering expenses. In addition, Soleno granted the underwriters a 30-day option to purchase up to an additional 352,941 shares of its common stock at the public offering price.
Events
Mintz x The Engine: Supercharging Your IP Strategy with Trade Secrets
The Engine, 750 Main St. Cambridge, MA 02139
Podcasts
Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|
Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|